Trials / Conditions / Primary Sjögren's Syndrome

Primary Sjögren's Syndrome

28 registered clinical trials studyying Primary Sjögren's Syndrome — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe NCT06979531	Immunovant Sciences GmbH	Phase 2
Completed	Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome NCT06484855	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1
Completed	Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syn NCT06203457	argenx	Phase 2
Completed	A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) NCT05817669	argenx	Phase 2
Completed	Acupuncture Combined With Hydroxychloroquine NCT06432101	Senyue Zhang	N/A
Recruiting	The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome NCT04981145	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 4
Unknown	Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome NCT05087589	Peking University People's Hospital	Phase 2
Unknown	The Profile of Fatigue and Discomfort - Sicca Symptoms Inventory NCT04975087	Gazi University	—
Completed	Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients NCT04605978	Institut de Recherches Internationales Servier	Phase 2
Unknown	Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questio NCT04858464	Gazi University	—
Terminated	BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome NCT04684654	Bristol-Myers Squibb	Phase 1
Completed	Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus NCT04186871	Bristol-Myers Squibb	Phase 2
Completed	A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome NCT04078386	RemeGen Co., Ltd.	Phase 2
Unknown	Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the NCT04212572	University Hospital, Brest	—
Completed	A Study of INCB050465 in Primary Sjögren's Syndrome NCT03627065	Incyte Corporation	Phase 2
Recruiting	Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity NCT03003572	Centre Hospitalier Universitaire de Saint Etienne	—
Recruiting	The ASSESS National Multi-center Prospective Cohort NCT03040583	Assistance Publique - Hôpitaux de Paris	—
Completed	Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome NCT02775916	Novartis Pharmaceuticals	Phase 2
Withdrawn	Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome NCT02495129	Novartis Pharmaceuticals	Phase 1 / Phase 2
Terminated	UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome NCT02610543	UCB Celltech	Phase 2
Completed	A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in P NCT02334306	MedImmune LLC	Phase 2
Completed	A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome NCT02464319	Peking University People's Hospital	Phase 2
Completed	Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome NCT02291029	Novartis Pharmaceuticals	Phase 2
Completed	PD of VAY736 in Patients With Primary Sjögren's Syndrome NCT02149420	Novartis Pharmaceuticals	Phase 2
Completed	Primary Sjögren Syndrome NCT01989819	University Hospital, Limoges	—
Terminated	Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome NCT01552681	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome NCT00632866	Assistance Publique - Hôpitaux de Paris	Phase 3
Completed	Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome NCT00426543	University of Copenhagen	Phase 2